Galmed Pharmaceuticals (EOCN) Set to Release Earnings on Wednesday

Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) will likely be posting its results on Wednesday, November 25th. Analysts expect Galmed Pharmaceuticals to post earnings of ($3.12) per share for the quarter.

Galmed Pharmaceuticals (NASDAQ:EOCN – Get Free Report) last posted its quarterly earnings data on Wednesday, September 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, topping the consensus estimate of ($3.12) by $0.26.

Galmed Pharmaceuticals Trading Down 2.8%

NASDAQ:EOCN opened at $2.46 on Wednesday. Galmed Pharmaceuticals has a 52-week low of $2.05 and a 52-week high of $10.08. The stock has a 50-day simple moving average of $3.69 and a 200 day simple moving average of $4.49.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Galmed Pharmaceuticals in a research note on Thursday, October 15th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Read Our Latest Research Report on EOCN

Galmed Pharmaceuticals Company Profile

(Get Free Report)

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy.

Read More

Earnings History for Galmed Pharmaceuticals (NASDAQ:EOCN)

Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.